CJC-1295 with Drug Affinity Complex leverages albumin binding to extend its half-life to 6�10 days, producing sustained 2�10-fold increases in growth hormone and multi-week elevations in IGF-1 from a single injection.
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered for dramatically prolonged action in the body. Unlike standard GHRH or the non-DAC version of CJC-1295 � which clear the bloodstream within 30 minutes � the DAC modification allows the peptide to covalently bind albumin, the most abundant protein in blood plasma. This albumin partnership effectively shields the molecule from enzymatic degradation, extending its half-life to an estimated 6�10 days.
The clinical significance of this mechanism is substantial. A landmark study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that a single injection of CJC-1295 produced dose-dependent 2�10-fold increases in mean plasma GH concentrations lasting six or more days, alongside 1.5�3-fold IGF-1 elevations that persisted for 9�11 days. With multiple doses, IGF-1 levels were maintained for up to 28 days � a sustained anabolic and regenerative environment that pulsatile secretagogues cannot replicate.
For body composition research, the implications are significant. GH and IGF-1 together drive protein synthesis, lipolysis, and cellular repair. The sustained elevation enabled by CJC-1295 with DAC means these processes are continuously supported rather than triggered only in brief daily windows. Researchers are particularly interested in applications for GH-deficient adults, aging-related sarcopenia, and visceral fat accumulation, where consistency of GH signaling matters more than peak amplitude.
Clinically, once-weekly dosing improves adherence compared to the multiple-daily-injection protocols required by shorter-acting GHRP compounds. As peptide therapeutics continue to gain traction in longevity medicine, CJC-1295 with DAC occupies a unique position: a well-characterized mechanism backed by Phase II human data, positioned at the intersection of convenience and sustained efficacy.
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.